TY  - GEN
AU  - Fleishaker,Dona L
AU  - Garcia Meijide,Juan A
AU  - Petrov,Andriy
AU  - Kohen,Michael David
AU  - Wang,Xin
AU  - Menon,Sujatha
AU  - Stock,Thomas C
AU  - Mebus,Charles A
AU  - Goodrich,James M
AU  - Mayer,Howard B
AU  - Zeiher,Bernhardt G
TI  - Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial
SN  - 1478-6362
PY  - 2012///1217
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antirheumatic Agents
KW  - adverse effects
KW  - Area Under Curve
KW  - Arthritis, Rheumatoid
KW  - drug therapy
KW  - CCR5 Receptor Antagonists
KW  - Constipation
KW  - chemically induced
KW  - Cyclohexanes
KW  - Dose-Response Relationship, Drug
KW  - Double-Blind Method
KW  - Drug Administration Schedule
KW  - Drug Therapy, Combination
KW  - Female
KW  - Humans
KW  - Male
KW  - Maraviroc
KW  - Metabolic Clearance Rate
KW  - Methotrexate
KW  - Middle Aged
KW  - Nausea
KW  - Treatment Failure
KW  - Triazoles
KW  - Young Adult
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1186/ar3685
ER  -